-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244

Benzinga·10/22/2026 11:38:22
Listen to the news
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.